Home > Boards > US OTC > Biotechs > Fortress BioTechnology (FBIO)

Avenue Therapeutics Reports Full Year 2018 Financial Results

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
conix Member Profile
 
Followed By 166
Posts 26,043
Boards Moderated 10
Alias Born 10/10/05
160x600 placeholder
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 11/4/2019 7:30:00 AM
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development GlobeNewswire Inc. - 10/28/2019 8:30:05 AM
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual ... GlobeNewswire Inc. - 10/18/2019 8:30:05 AM
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 8/14/2019 7:30:00 AM
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors GlobeNewswire Inc. - 8/1/2019 8:00:00 AM
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Manageme... GlobeNewswire Inc. - 6/3/2019 7:00:00 AM
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 5/13/2019 7:30:00 AM
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors GlobeNewswire Inc. - 4/30/2019 7:30:00 AM
Market Trends Toward New Normal in Colgate-Palmolive, Nucor, NeoPhotonics, Piper Jaffray Companies, The Ensign Group, and For... GlobeNewswire Inc. - 4/3/2019 8:45:00 AM
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 3/12/2019 7:30:00 AM
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary) GlobeNewswire Inc. - 2/11/2019 7:30:00 AM
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for th... GlobeNewswire Inc. - 12/19/2018 8:00:00 AM
conix   Tuesday, 03/12/19 10:16:00 AM
Re: trendmkr post# 11
Post # of 57 
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

-- Expects to Report Topline Data from Phase 3 Trial of IV Tramadol in Patients Following Abdominoplasty Surgery in mid-2019 --




NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the year ended December 31, 2018.

“2018 was an exciting year for Avenue. We announced positive data from our first pivotal Phase 3 trial evaluating IV tramadol in patients following bunionectomy surgery in May, and signed a two-stage equity investment and contingent acquisition agreement with InvaGen Pharmaceuticals Inc. (“InvaGen”), a subsidiary of Cipla Limited, in November,” said Lucy Lu, MD, Avenue’s President and Chief Executive Officer. “The first stage of the transaction closed in February of 2019 and we look forward to reporting topline data from our second Phase 3 trial in patients following abdominoplasty surgery in the coming months.”

2018 and Recent Corporate Highlights:

In May 2018, we announced that our first pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours compared to placebo in patients with moderate to moderately severe postoperative pain following bunionectomy surgery. In addition, the trial met its key secondary endpoints and demonstrated a clear dose response.
In November 2018, we announced definitive agreements regarding an equity investment and contingent acquisition of Avenue by InvaGen, a subsidiary of Cipla Limited, a leading pharmaceutical company. The first stage of the transaction closed in February 2019, and InvaGen acquired 5,833,333 shares of our common stock at $6.00 per share for total gross proceeds of $35.0 million, representing a 33.3% stake in Avenue’s capital stock on a fully diluted basis.
In December 2018, we announced that the first patient has been dosed in a pivotal Phase 3 clinical trial of IV tramadol for the management of moderate to moderately severe pain in patients following abdominoplasty surgery. Topline data is expected to be available in mid-2019.

2018 Financial Results:

Cash Position: As of December 31, 2018, our cash and short-term investments totaled $2.7 million, compared to $21.8 million at December 31, 2017, a decrease of $19.1 million. However, on February 8, 2019, we completed the first stage of the Acquisition agreement and we sold 5,833,333 shares of our common stock to InvaGen for total gross proceeds of $35.0 million.
R&D Expenses: Research and development expenses for the full year 2018 were $17.7 million, compared to $6.7 million in 2017. This increase of $11.0 million was primarily attributable to the completion of our bunionectomy study, continuation of our safety study and the initiation of our abdominoplasty study.
G&A Expenses: General and administrative expenses for the full year 2018 were $4.1 million, compared to $3.6 million in 2017. This increase of $0.5 million was primarily attributable to increases in legal costs and other professional fees partially offset by non-cash stock compensation expenses.
Net Loss: Net loss attributable to common stockholders for the full year 2018 was $21.5 million, or $2.10 per share, compared to a net loss of $12.3 million, or $1.85 per share, in 2017.

About Avenue Therapeutics
Avenue, a company founded by Fortress Biotech, is a specialty pharmaceutical company focused on the development and commercialization of IV Tramadol for the management of moderate to moderately severe post-operative pain. IV Tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDs and IV conventional narcotics. Avenue is currently evaluating IV Tramadol in a pivotal Phase 3 program for the management of post-operative pain. Avenue is headquartered in New York City. For more information, visit www.avenuetx.com.

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) (NASDAQ: FBIO) is an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries and at entities it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital and UCL Business PLC. For more information, visit www.fortressbiotech.com.

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist